However, several important challenges remain before such therapies can be used in the clinical setting, including the need to ensure their bioavailability at the primary site of infection, the lungs.3 Prior work has shown that iNK T cells control intracellular Mtb infection by secreting the antimicrobial cytokine GM-CSF.47 In the current study, we used an albumin-fusion strategy to enhance delivery of GM-CSF to the lungs and dLNs. The gene discussed is ALB; the disease is infection.